|
1
|
Kim SI, Kim HS, Kim TH, Suh DH, Kim K, No
JH, Chung HH, Kim YB and Song YS: Impact of underweight after
treatment on prognosis of advanced-stage ovarian cancer. J Immunol
Res. 2014:3495462014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barber A, Zhang T and Sentman CL:
Correction: immunotherapy with chimeric NKG2D receptors leads to
long-term tumor-free survival and development of host antitumor
immunity in murine ovarian cancer. J Immunol. 193:15132014.
|
|
3
|
Muralidhar GG and Barbolina MV: Chemokine
receptors in epithelial ovarian cancer. Int J Mol Sci. 15:361–376.
2013. View Article : Google Scholar
|
|
4
|
Shen CC, Kang YH, Zhao M, He Y, Cui DD, Fu
YY, Yang LL and Gou LT: WNT16B from ovarian fibroblasts induces
differentiation of regulatory T cells through β-catenin signal in
dendritic cells. Int J Mol Sci. 15:12928–12939. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu J, Li J, Zhang JF and Xin XY:
Combination of fenretinide and selenite inhibits proliferation and
induces apoptosis in ovarian cancer cells. Int J Mol Sci.
14:21790–21804. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ekinci T, Ozbay PO, Yiğit S, Yavuzcan A,
Uysal S and Soylu F: The correlation between immunohistochemical
expression of MMP-2 and the prognosis of epithelial ovarian cancer.
Ginekol Pol. 85:121–130. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grelewski PG and Bar JK: The role of p53
protein and MMP-2 tumor/stromal cells expression on progressive
growth of ovarian neoplasms. Cancer Invest. 31:472–479. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S
and Fu S: Id1 enhances human ovarian cancer endothelial progenitor
cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways.
J Transl Med. 11:1322013. View Article : Google Scholar
|
|
9
|
Laios A, Mohamed BM, Kelly L, Flavin R,
Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, et al:
Pre-treatment of platinum resistant ovarian cancer cells with an
MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as
determined by high content screening. Int J Mol Sci. 14:2085–2103.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu DW, Hsu NY, Wang YC, Lee MC, Cheng YW,
Chen CY and Lee H: c-Myc suppresses microRNA-29b to promote tumor
aggressiveness and poor outcomes in non-small cell lung cancer by
targeting FHIT. Oncogene. 34:2072–2082. 2015. View Article : Google Scholar
|
|
11
|
Parpart S, Roessler S, Dong F, Rao V,
Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY, et al: Modulation of
miR-29 expression by α-fetoprotein is linked to the hepatocellular
carcinoma epigenome. Hepatology. 60:872–883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Z, Huang X, Huang X, Zou Q and Guo Y:
The inhibitory role of Mir-29 in growth of breast cancer cells. J
Exp Clin Cancer Res. 32:982013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan M, Wu J and Cai Y: Suppression of Wnt
signaling by the miR-29 family is mediated by demethylation of
WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Commun.
438:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang C, Bian Z, Wei D and Zhang JG:
miR-29b regulates migration of human breast cancer cells. Mol Cell
Biochem. 352:197–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu PN, Yan MD, Lai HC, Huang RL, Chou YC,
Lin WC, Yeh LT and Lin YW: Downregulation of miR-29 contributes to
cisplatin resistance of ovarian cancer cells. Int J Cancer.
134:542–551. 2014. View Article : Google Scholar
|
|
16
|
Creighton CJ, Hernandez-Herrera A,
Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson
E, Sheridan R, et al: Integrated analyses of microRNAs demonstrate
their widespread influence on gene expression in high-grade serous
ovarian carcinoma. PLoS One. 7:e345462012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu XS, Yang T, Gu J, Li ML, Wu WG, Weng H,
Ding Q, Mu JS, Bao RF, Shu YJ, et al: Effects of oxymatrine on the
apoptosis and proliferation of gallbladder cancer cells. Anticancer
Drugs. 25:1005–1015. 2014. View Article : Google Scholar
|
|
18
|
Yang Z, Yin R, Cong Y, Yang Z, Zhou E, Wei
Z, Liu Z, Cao Y and Zhang N: Oxymatrine lightened the inflammatory
response of LPS-induced mastitis in mice through affecting NF-κB
and MAPKs signaling pathways. Inflammation. 37:2047–2055. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu
W, Qi X, Zhu X, Pei Y and Lin H: Oxymatrine diminishes the side
population and inhibits the expression of β-catenin in MCF-7 breast
cancer cells. Med Oncol. 28(Suppl 1): S99–S107. 2011. View Article : Google Scholar
|
|
20
|
Zhang Y, Liu H, Jin J, Zhu X, Lu L and
Jiang H: The role of endogenous reactive oxygen species in
oxymatrine-induced caspase-3-dependent apoptosis in human melanoma
A375 cells. Anticancer Drugs. 21:494–501. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu C, Huang W, Guo Y, et al: Oxymatrine
inhibits the proliferation of prostate cancer cells in vitro and in
vivo. Mol Med Rep. 11:4129–4134. 2015.PubMed/NCBI
|
|
22
|
Chen H, Zhang J, Luo J, Lai F, Wang Z,
Tong H, Lu D, Bu H, Zhang R and Lin S: Antiangiogenic effects of
oxymatrine on pancreatic cancer by inhibition of the NF-κB-mediated
VEGF signaling pathway. Oncol Rep. 30:589–595. 2013.PubMed/NCBI
|
|
23
|
Ho JW, Ngan Hon PL and Chim WO: Effects of
oxymatrine from Ku Shen on cancer cells. Anticancer Agents Med
Chem. 9:823–826. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong XQ, Du Q, Yu WH, Zhang ZY, Zhu Q, Che
ZH, Chen F, Wang H and Chen J: Anti-inflammatory effects of
oxymatrine through inhibition of nuclear factor-kappa B and
mitogen-activated protein kinase activation in
lipopolysaccharide-induced BV2 Microglia Cells. Iran J Pharm Res.
12:165–174. 2013.PubMed/NCBI
|
|
25
|
Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang
B and Zheng S: Oxymatrine induces human pancreatic cancer PANC-1
cells apoptosis via regulating expression of Bcl-2 and IAP
families, and releasing of cytochrome c. J Exp Clin Cancer Res.
30:662011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seo JM, Park S and Kim JH: Leukotriene B4
receptor-2 promotes invasiveness and metastasis of ovarian cancer
cells through signal transducer and activator of transcription 3
(STAT3)-dependent up-regulation of matrix metalloproteinase 2. J
Biol Chem. 287:13840–13849. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang
HH, Liu X, Liang DS, Lu YJ, Shan HL, et al: Matrine inhibits breast
cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell
Physiol Biochem. 30:631–641. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Sun S, Chen J, Ren P, Hu Y, Cao
Z, Sun H and Ding Y: Oxymatrine induces mitochondria dependent
apoptosis in human osteosarcoma MNNG/HOS cells through inhibition
of PI3K/Akt pathway. Tumour Biol. 35:1619–1625. 2014. View Article : Google Scholar
|
|
29
|
Gong J, Li J, Wang Y, Liu C, Jia H, Jiang
C, Wang Y, Luo M, Zhao H, Dong L, et al: Characterization of
microRNA-29 family expression and investigation of their
mechanistic roles in gastric cancer. Carcinogenesis. 35:497–506.
2014. View Article : Google Scholar
|
|
30
|
Jiang H, Zhang G, Wu JH and Jiang CP:
Diverse roles of miR-29 in cancer (review). Oncol Rep.
31:1509–1516. 2014.PubMed/NCBI
|
|
31
|
Cittelly DM, Finlay-Schultz J, Howe EN,
Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA and
Richer JK: Progestin suppression of miR-29 potentiates
dedif-ferentiation of breast cancer cells via KLF4. Oncogene.
32:2555–2564. 2013. View Article : Google Scholar
|
